G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. SPOT
6. BYD
7. WCN
8. IVBIY
9. FIX
10. NDAQ

Go back to G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

August 2, 2023 6:30 AM EDT

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue -

- Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 -

- Presented New Phase 2 Results Confirming Benefit of Trilaciclib in Reducing Adverse Events Associated with an Antibody-Drug Conjugate (ADC) in Triple Negative Breast Cancer (TNBC) -

- Provided Phase 2 Mechanism of Action Trial Results Clarifying Trilaciclib's Role in Enhancing Immune Surveillance and Efficacy as Measured by Long Term... More